Abstract |
Antimicrobial therapy can have a significant impact in the treatment of acute infectious exacerbations in patients with chronic bronchitis, in whom repeated episodes are common. The aim of this randomised, double-blind, double-dummy, parallel group study was to compare the efficacy and safety of oral gatifloxacin (200 and 400 mg once daily) administered for 5 days with co-amoxiclav (500 mg amoxicillin/125 mg clavulanic acid t.i.d.) administered for 10 days in 414 adult patients with acute exacerbation of chronic bronchitis. Overall clinical response rates (cure plus improvement) were 86.2%, 79.4% and 81.7% in the gatifloxacin 200 mg, gatifloxacin 400 mg and co-amoxiclav groups, respectively, and the equivalence hypothesis used for statistical analysis showed equivalent efficacy for both gatifloxacin 200 and 400 mg compared to co-amoxiclav. The same was true for rates of bacterial response, with eradication or presumed eradication of causative pathogens achieved in 87.5%, 87.3% and 79.1% of cases in the gatifloxacin 200 mg, gatifloxacin 400 mg and co-amoxiclav groups, respectively. All treatments were well tolerated, with the nature and frequency of treatment-related adverse events similar in all groups. The results of the study show that gatifloxacin is a safe and effective agent for the treatment of patients with chronic bronchitis experiencing an acute infectious exacerbation.
|
Authors | M Solèr, H Lode, R Baldwin, J H A Levine, A J M Schreurs, J A van Noord, F P V Maesen, M Zehrer, European Gatifloxacin Study group |
Journal | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
(Eur J Clin Microbiol Infect Dis)
Vol. 22
Issue 3
Pg. 144-50
(Mar 2003)
ISSN: 0934-9723 [Print] Germany |
PMID | 12649711
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Amoxicillin-Potassium Clavulanate Combination
- Gatifloxacin
|
Topics |
- Administration, Oral
- Amoxicillin-Potassium Clavulanate Combination
(administration & dosage, adverse effects, therapeutic use)
- Anti-Infective Agents
(administration & dosage, adverse effects, therapeutic use)
- Bacteria
(classification, isolation & purification)
- Bacterial Infections
(drug therapy)
- Bronchitis, Chronic
(drug therapy, microbiology)
- Double-Blind Method
- Drug Administration Schedule
- Female
- Fluoroquinolones
- Gatifloxacin
- Humans
- Male
- Partial Pressure
- Treatment Outcome
- Vital Capacity
|